“Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s143. doi:10.25251/skin.7.supp.143.